- Home
- RDIB vs DRTS Comparison
RDIB vs DRTS Comparison
Compare RDIB & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- DRTS
- Stock Information
- Founded
- RDIB 1937
- DRTS 2015
- Country
- RDIB United States
- DRTS Israel
- Employees
- RDIB N/A
- DRTS N/A
- Industry
- RDIB Movies/Entertainment
- DRTS Medical/Dental Instruments
- Sector
- RDIB Consumer Discretionary
- DRTS Health Care
- Exchange
- RDIB Nasdaq
- DRTS Nasdaq
- Market Cap
- RDIB 279.6M
- DRTS 300.2M
- IPO Year
- RDIB N/A
- DRTS N/A
- Fundamental
- Price
- RDIB $12.91
- DRTS $3.81
- Analyst Decision
- RDIB
- DRTS Strong Buy
- Analyst Count
- RDIB 0
- DRTS 1
- Target Price
- RDIB N/A
- DRTS $9.00
- AVG Volume (30 Days)
- RDIB 6.3K
- DRTS 63.6K
- Earning Date
- RDIB 08-14-2025
- DRTS 08-11-2025
- Dividend Yield
- RDIB N/A
- DRTS N/A
- EPS Growth
- RDIB N/A
- DRTS N/A
- EPS
- RDIB N/A
- DRTS N/A
- Revenue
- RDIB $219,213,000.00
- DRTS N/A
- Revenue This Year
- RDIB $5.21
- DRTS N/A
- Revenue Next Year
- RDIB $11.45
- DRTS N/A
- P/E Ratio
- RDIB N/A
- DRTS N/A
- Revenue Growth
- RDIB 7.59
- DRTS N/A
- 52 Week Low
- RDIB $5.78
- DRTS $2.11
- 52 Week High
- RDIB $14.95
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- RDIB 55.20
- DRTS 66.03
- Support Level
- RDIB $11.94
- DRTS $3.51
- Resistance Level
- RDIB $12.95
- DRTS $3.99
- Average True Range (ATR)
- RDIB 0.93
- DRTS 0.18
- MACD
- RDIB -0.14
- DRTS 0.04
- Stochastic Oscillator
- RDIB 60.98
- DRTS 80.00
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.